

# Patent granted in Japan

Cancer treatment company Lithea AB (“Lithea” or the “Company”), developer of the LIT-platform – a technology enabling local treatment of solid tumours with an enhanced anti-cancer effect – today announces that the Company has received a Certificate of Patent from the Japan Patent Office (JPO). This means that the JPO has approved the patent application and registered the patent making it valid until 2041. This is the Company’s first patent to be granted in Japan for the LIT-platform technology.

The patent provides the LIT-platform protection for treating cancer using the LIT-platform to deliver pharmaceutical drugs. Lithea has patents granted to date in Europe, Japan, and Singapore, with late-stage applications in the USA and China.

“We are proud to announce that Lithea has secured patent approval in Japan. This milestone underscores our commitment to innovation and strengthens our position in delivering cutting-edge intratumoral therapies to patients worldwide. It also underscores our organization’s ability to generate patentable inventions.” —Ludvig Sjöberg, CEO of Lithea

For more information about Lithea, please contact:

Ludvig Sjöberg, CEO

[ludvig.sjoberg@lithea-pharma.com](mailto:ludvig.sjoberg@lithea-pharma.com)

January 27, 2026

Lund, Sweden

## About Lithea

*Lithea is a pharma startup company developing innovative treatment options for cancer. Our mission is to prolong the lives of cancer patients. Lithea’s patented technology platform is based on research done by the founders of the company at Lund University for using bone minerals as a drug delivery system of anticancer substances to solid tumour cancer patients. Our first lead asset under development is called LIT1001 and it is for targeted treatment of osteosarcoma tumours. For more information, please visit [www.lithea-pharma.com](http://www.lithea-pharma.com).*